Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 68788-8625

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68788-8625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical structure of atorvastatin calcium showing the calcium ion and the atorvastatin molecular structure including hydroxyl groups, fluorophenyl, and other functional groups. The image depicts the hydrated form with 3 water molecules included.*

FDA Label Image

Atorvastatin Calcium Tablets 20mg (Container Label 20mg)

Atorvastatin Calcium Tablets 20 mg film-coated tablet packaging label. The label includes the generic name atorvastatin calcium and states it is generic for Lipitor. Directions for use are provided in English and Spanish. The label mentions storage instructions at 20°-25°C and includes manufacturer details as Recipharm Pharmaservices Pvt. Ltd. The label is from Preferred Pharmaceuticals Inc.*

FDA Label Image

Figure 1.jpg (Figure1)

A line chart comparing the cumulative incidence percentage over time in years for Atorvastatin and placebo groups. The chart shows two curves, with Atorvastatin represented by a solid line and placebo by a dashed line, indicating lower cumulative incidence for Atorvastatin over a 3.5-year period.*

FDA Label Image

Figure 2.jpg (Figure2)

A line chart showing cumulative hazard percentage over time in years up to five years. It compares Atorvastatin versus placebo, illustrating lower cumulative hazard for Atorvastatin (solid line) compared to placebo (dashed line) from time to first primary endpoint through four years of follow-up.*

FDA Label Image

Figure 3.jpg (Figure3)

A line graph showing the percentage of subjects experiencing a major cardiovascular event over time in years for Atorvastatin 10 mg and 80 mg doses. The x-axis represents time to first major cardiovascular endpoint in years, and the y-axis shows the percentage of subjects experiencing the event. The 80 mg dose line is consistently below the 10 mg dose line, with a hazard ratio of 0.78 and a p-value of 0.0002 indicated on the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.